Article
Design and synthesis of pyrrolidine-5,50-trans-lactams (5-oxo-
Journal of Medicinal Chemistry, 2010, Vol. 53, No. 8 3245
(20) Metabolite determination for compound 6 showed that its main
metabolites are the corresponding N-oxide, a benzylic alcohol, and
the primary alcohol resulting from attack on the tert-butyl group.
(21) Fischer, H.; Kansy, M.; Bur, D. CAFCA: a novel tool for the
calculation of amphiphilic properties of charged drug molecules.
Chimia 2000, 54 (11), 640–645.
(22) Cavalli, A.; Poluzzi, E.; De Ponti, F.; Recanatini, M. Toward a
pharmacophore for drugs inducing the long QT syndrome: Insights
from a CoMFA study of HERG Kþ channel blockers. J. Med.
Chem. 2002, 45 (18), 3844–3853.
(23) Compared to what was to be expected based on the pKa shifts in the
open chain, the extent to which this calculated decrease is realized
in various heterocycles is as follows: piperidine 27, 77%; pyrroli-
dine 21, 62%; azetidine 15, 39% of the theoretical value. Theore-
tical values were calculated by adding the appropriate pKa shifts of
the open chain, e.g., for piperidine 24, ΔpKa(β) þ ΔpKa(δ).
(24) Morgenthaler, M.; Schweizer, E.; Hoffmann-Roder, A.; Benini, F.;
Martin, R. E.; Jaeschke, G.; Wagner, B.; Fischer, H.; Bendels, S.;
hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors
of human cytomegalovirus protease. 4. Antiviral activity and plasma
stability. J. Med. Chem. 2003, 46 (21), 4428–4449. (c) Addition of
steric bulk can help to reduce glucuronidation (phase II metabolism):
Madsen, P.; Ling, A.; Plewe, M.; Sams, C. K.; Knudsen, L. B.;
Sidelmann, U. G.; Ynddal, L.; Brand, C. L.; Andersen, B.; Murphy,
D.; Teng, M.; Truesdale, L.; Kiel, D.; May, J.; Kuki, A.; Shi, S. H.;
Johnson, M. D.; Teston, K. A.; Feng, J.; Lakis, J.; Anderes, K.; Gregor,
V.; Lau, J. Optimization of alkylidene hydrazide based human glucagon
receptor antagonists. Discovery of the highly potent and orally available
3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-
indol-4-ylmethylene]hydrazide. J. Med. Chem. 2002, 45 (26), 5755–
5775.
(8) For examples, see the following: (a) Duffy, J. L.; Rano, T. A.;
Kevin, N. J.; Chapman, K. T.; Schleif, W. A.; Olsen, D. B.;
Stahlhut, M.; Rutkowski, C. A.; Kuo, L. C.; Jin, L. X.; Lin, J.
H.; Emini, E. A.; Tata, J. R. HIV protease inhibitors with pico-
molar potency against PI-resistant HIV-1 by extension of the P-3
substituent. Bioorg. Med. Chem. Lett. 2003, 13 (15), 2569–2572. (b)
Ahmad, S.; Doweyko, L. M.; Dugar, S.; Grazier, N.; Ngu, K.; Wu, S. C.;
Yost, K. J.; Chen, B. C.; Gougoutas, J. Z.; DiMarco, J. D.; Lan, S. J.;
Gavin, B. J.; Chen, A. Y.; Dorso, C. R.; Serafino, R.; Kirby, M.; Atwal,
K. S. Arylcyclopropanecarboxyl guanidines as novel, potent, and
selective inhibitors of the sodium hydrogen exchanger isoform-1.
J. Med. Chem. 2001, 44 (20), 3302–3310.
€
Zimmerli, D.; Schneider, J.; Diederich, F.; Kansy, M.; Muller, K.
Predicting properties and tuning physicochemical in lead optimiza-
tion: amine basicities. ChemMedChem 2007, 2 (8), 1100–1115.
(25) NMR analysis of the protonated pyrrolidine 18 did not give a clear
picture of the preferred conformation. This is probably due to the
high conformational flexibility of five-membered rings.
(26) Greig, I. R.; Tozer, M. J.; Wright, P. T. Synthesis of cyclic
sulfonamides through intramolecular Diels-Alder reactions.
Org. Lett. 2001, 3 (3), 369–371.
(9) Vinyl-substituted carbonyl compounds are not present in marketed
drugs (Prous Science Integrity, May 2008).
(10) Search on MDL Metabolite Database and Prous Science Integrity
(May 2008) for metabolic reactions yielded no hits.
(27) Venkatachalam, T. K.; Sudbeck, E.; Uckun, F. M. Structural
influence on the anisotropic intermolecular hydrogen bonding in
solid state of substituted thioureas: evidence by X-ray crystal
structure. J. Mol. Struct. 2004, 687 (1-3), 45–56.
(11) Prous Science Integrity, May 2008: Substructure search for
launched compounds containing a morpholine unit: (a) McKillop,
D.; McCormick, A. D.; Miles, G. S.; Phillips, P. J.; Pickup, K. J.;
Bushby, N.; Hutchison, M. In vitro metabolism of gefitinib in
human liver microsomes. Xenobiotica 2004, 34 (11), 983–1000. (b)
Balani, S. K.; Pitzenberger, S. M.; Schwartz, M. S.; Ramjit, H. G.;
Thompson, W. J. Metabolism of L-689,502 by rat-liver slices to potent
HIV-1 protease inhibitors. Drug Metab. Dispos. 1995, 23 (2), 185–
189. (c) Hayashi, T.; Aoyama, M.; Fukuda, M.; Ohki, M.; Kishikawa, T.
Metabolism of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone
(M73101), a new anti-inflammatory agent. 2. Species-differences of
metabolism and excretion. Chem. Pharm. Bull. 1979, 27 (2), 317–325.
(d) Giraldi, P. N.; Tosolini, G. P.; Dradi, E.; Nannini, G.; Longo, R.;
Meinardi, G.; Monti, G.; Carneri, I. D. Studies on antiprotozoans. 3.
Isolation, identification and quantitative determination in humans of
metabolites of a new trichomonacidal agent. Biochem. Pharmacol.
1971, 20 (2), 339. (e) Betts, A.; Atkinson, F.; Gardner, I.; Fox, D.;
Webster, R.; Beaumont, K.; Morgan, P. Impact of physicochemical
and structural properties on the pharmacokinetics of a series of alpha
1(L)-adrenoceptor antagonists. Drug Metab. Dispos. 2007, 35 (8),
1435–1445. (f) Jauch, R.; Griesser, E.; Oesterhelt, G.; Arnold, W.;
Meister, W.; Ziegler, W. H.; Guentert, T. W. Biotransformation of
moclobemide in humans. Acta Psychiatr. Scand., Suppl. 1990, 360,
87. (g) Coutts, R. T.; Jamali, F.; Malek, F.; Peliowski, A.; Finer, N. N.
Urinary metabolites of doxapram in premature neonates. Xenobiotica
1991, 21 (10), 1407–1418.
(12) A search in the Cambridge Structural Database (CSD), version
5.30 (November 2008), for oxetanes, unsubstituted in 2- and 4-
positions and carrying only one or two hydrogen atoms or CH2X
groups in the 3-position (X = H, C, N, O, F, Si, P, S, Cl, Br, I)
yielded nine entries for 3,3-disubstituted and two entries for
unsubstituted oxetane.
(13) All references to the CSD in this paper refer to the Cambridge
Structural Database, version 5.30 (November 2008).
(14) Chan, S. I.; Zinn, J.; Fernandez, J.; Gwinn, W. D.; Trimethylene
Oxide, I. Microwave spectrum, dipole moment, and double mini-
mum vibration. J. Chem. Phys. 1960, 33 (6), 1643–1655.
€
(28) Muller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals:
looking beyond intuition. Science 2007, 317 (5846), 1881–1886.
€
€
(29) Bohm, H. J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Muller,
K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry.
ChemBioChem 2004, 5 (5), 637–643.
(30) Berthelot, M.; Besseau, F.; Laurence, C. The hydrogen-bond
basicity pKHB scale of peroxides and ethers. Eur. J. Org. Chem.
1998, No. 5, 925–931. The equilibrium concentrations were determined
by measuring the absorbances of the O-H stretching of 4-fluorophenol
for different initial base concentrations.
(31) Brandon, M.; Tamres, M.; Searles, S. The iodine complexes of
some saturated cyclic ethers. 1. The visible region. J. Am. Chem.
Soc. 1960, 82 (9), 2129–2134.
(32) Sisler, H. H.; Perkins, P. E. Molecular addition compounds of
dinitrogen tetroxide. 6. Binary systems with trimethylene oxide,
2,5-dimethyl tetrahydrofuran and 1,3-dioxolane. J. Am. Chem.
Soc. 1956, 78 (6), 1135–1136.
(33) Bennett, G. M.; Philip, W. G. The influence of structure on the
solubilities of ethers. Part II. Some cyclic ethers. J. Chem. Soc.
1928, 1937–1942.
(34) Korolev, A. M.; Eremenko, L. T.; Meshikhina, L. V.; Eremenko, I.
L.; Aleksandrov, G. G.; Konovalova, N. P.; Lodygina, V. P. Izv.
Akad. Nauk SSSR, Ser. Khim. 2003, 1763.
(35) IVAGUH: Korolev, A. M.; Eremenko, L. T.; Meshikhina, L. V.;
Eremenko, I. L.; Aleksandrov, G. G.; Konovalova, N. P.; Lodygina,
V. P.Synthesis and study of organic nitrates of heterofunctional
series 5. Synthesis of 3,3-bis(hydroxymethyl)oxetane mono-
and dinitrates and 2,2-bis(hydroxymethyl)propane-1,3-diol
(pentaerythritol) mono- and dinitrates. Russ. Chem. Bull. 2003,
52 (8), 1859–1863.
(36) CCDC 721350 (41) and CCDC 721113 (42) contain the supple-
mentary crystallographic data for this paper. These data can be
obtained free of charge from the Cambridge Crystallographic Data
(37) Data taken from ref 36. For a definition of log KHB and the method
used to determine it, see the following: Berthelot, M.; Besseau, F.;
Laurence, C. The hydrogen-bond basicity pKHB scale of peroxides and
ethers. Eur. J. Org. Chem. 1998, No. 5, 925–931.
(15) On the basis of these results, one would predict that ring closures
leading to spirocyclic oxetanes are faster than for their gem-
dimethyl analogues.
(38) For the H-bonding affinity of oxetanes, see ref 37. For related studies
with a variety of carbonyl compounds, see the following: (a) Besseau,
F.; Lucon, M.; Laurence, C.; Berthelot, M. Hydrogen-bond basicity
pK(HB) scale of aldehydes and ketones. J. Chem. Soc., Perkin Trans.
2 1998, No. 1, 101–107. (b) Besseau, F.; Laurence, C.; Berthelot, M.
Hydrogen-bond basicity of esters, lactones and carbonates. J. Chem.
Soc., Perkin Trans. 2 1994, No. 3, 485–489. (c) Lequestel, J. Y.;
Laurence, C.; Lachkar, A.; Helbert, M.; Berthelot, M. Hydrogen-bond
basicity of secondary and tertiary amides, carbamates, ureas and
lactams. J. Chem. Soc., Perkin Trans. 2 1992, No. 12, 2091–2094.
(39) Searles, S. The reaction of trimethylene oxide with Grignard
reagents and organolithium compounds. J. Am. Chem. Soc. 1951,
73 (1), 124–125.
(16) For ketones and gem-dimethyl derivatives, R was defined as
tetrahedral carbon. For oxetane derivatives, R was relaxed to allow
for elements C, N, O, Si, P, S, F, Cl, Br, I.
(17) Edward, J. T.; Farrell, P. G.; Shahidi, F. Partial molar volumes
of organic compounds in water. Part 1. Ethers, ketones, esters,
and alcohols. J. Chem. Soc., Faraday Trans. 1 1977, 73 (5), 705–
714.
(18) Zhou, T. L.; Battino, R. Partial molar volumes of 13 gases in water
at 298.15 and 303.15 K. J. Chem. Eng. Data 2001, 46 (2), 331–332.
(19) While the partial molar volume of formaldehyde in water is not
available, an upper limit can be estimated from the partial molar
volume of ethylene in water, 45.4 cm3/mol at 25 °C (ref 16).